• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIOSENSE WEBSTER INC UNK_SMART TOUCH BIDIRECTIONAL SF; CARDIAC ABLATION PERCUTANEOUS CATHETER

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIOSENSE WEBSTER INC UNK_SMART TOUCH BIDIRECTIONAL SF; CARDIAC ABLATION PERCUTANEOUS CATHETER Back to Search Results
Catalog Number UNK_SMART TOUCH BIDIRECTIONAL
Device Problem Patient Device Interaction Problem (4001)
Patient Problems Cardiac Tamponade (2226); Vascular Dissection (3160); Heart Block (4444)
Event Date 09/28/2022
Event Type  Injury  
Manufacturer Narrative
This complaint is from a literature source.The following literature cite has been reviewed: dukkipati sr, nakamura t, nakajima i, oates c, narui r, tanigawa s, sljapic t, whang w, koruth js, choudry s, schaeffer b, fujii a, tedrow ub, sapp jl, stevenson wg, reddy vy.Intramural needle ablation for refractory premature ventricular contractions.Circ arrhythm electrophysiol.2022 may;15(5):e010020.Doi: 10.1161/circep.121.010020.Epub 2022 apr 27.Pmid: 35476455.No device was received for analysis at the time of submission of the initial 3500a.Since the product was not returned for analysis, no product failure analysis can be conducted, and no determination of possible contributing factors could be made.Device history record (dhr) review cannot be conducted because the lot number was provided by the customer.This report is being submitted pursuant to the provisions of 21 cfr, part 4.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by biosense webster inc, or its employees that the report constitutes an admission that the product, biosense webster inc, or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.Manufacturer¿s reference number: (b)(4).
 
Event Description
This complaint is from a literature source.The following literature cite has been reviewed: dukkipati sr, nakamura t, nakajima i, oates c, narui r, tanigawa s, sljapic t, whang w, koruth js, choudry s, schaeffer b, fujii a, tedrow ub, sapp jl, stevenson wg, reddy vy.Intramural needle ablation for refractory premature ventricular contractions.Circ arrhythm electrophysiol.2022 may;15(5):e010020.Doi: 10.1161/circep.121.010020.Epub 2022 apr 27.Pmid: 35476455.Objective and methods: background: frequent premature ventricular contractions (pvcs) are often amenable to catheter ablation.However, a deep intramural focus may lead to failure due to inability of standard ablation techniques to penetrate the focus.We sought to assess the efficacy and safety of infusion needle ablation (ina) for pvcs that are refractory to standard radiofrequency ablation.Methods: under 2 food and drug administration approved protocols, ina was evaluated in patients with frequent pvcs that were refractory to standard ablation.Initial targets for ablation were selected by standard mapping techniques.Ina was performed with a deflectable catheter equipped with an extendable/retractable needle at the tip that can be extended up to 12 mm into the myocardium and is capable of pacing and recording.After contrast injection for location assessment, radiofrequency ablation was performed with the needle tip using a temperature-controlled mode (maximum temperature 60 °c) with saline infusion from the needle.The primary end point was a decrease in pvc burden to <5000/24 hours at 6 months.The primary safety end point was incidence of procedure- or device-related serious adverse events.Results: at 4 centers, 35 patients (age 55.3±16.9 years, 74.2% male) underwent ina.The baseline median pvc burden was 25.4% (interquartile range, 18.4%-33.9%) and mean left ventricular ejection fraction was 37.7±12.3%.Delivering 10.3±8.0 ina lesions/patient (91% had adjunctive standard radiofrequency ablation also) resulted in acute pvc elimination in 71.4%.After a mean follow-up of 156±109 days, the primary efficacy end point was met in 73.3%.The median pvc burden decreased to 0.8% (interquartile range, 0.1%-6.0%; p<0.001).The primary safety end point occurred in 14.3% consisting of 1 (2.9%) heart block, 1 (2.9%) femoral artery dissection, and 3 (8.6%) pericardial effusions (all treated percutaneously).Conclusions: ina is effective for the elimination of frequent pvcs that are refractory to conventional ablation and is associated with an acceptable safety profile lot, model and catalog number are not available, but the suspected biosense webster device possibly associated with reported adverse events: 3.5-mm irrigated tip contact force sensing catheter: thermocool smarttouch.Other biosense webster devices that were also used in this study: carto 3d, multielectrode mapping catheter: pentaray nav.Non-biosense webster devices that were also used in this study: intracardiac electrograms were continuously recorded on an electrophysiology recording system¿either a labsystem pro (boston scientific) or cardiolab (general electric healthcare).Unknown needle ablation catheter: 8-f deflectable catheter with a distal bipole consisting of dome and ring lectrodes.Adverse event(s) and provided interventions: 3 pericardial effusions requiring pericardiocentesis.1 intermittent complete heart block during needle advancement: no treatment specified.1 femoral artery dissection requiring percutaneous intervention.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
UNK_SMART TOUCH BIDIRECTIONAL SF
Type of Device
CARDIAC ABLATION PERCUTANEOUS CATHETER
Manufacturer (Section D)
BIOSENSE WEBSTER INC
31 technology drive, suite 200
irvine CA 92618
Manufacturer (Section G)
BIOSENSE WEBSTER INC (JUAREZ)
circuito interior norte
1820parque industrial salvacar
juarez 32599
MX   32599
Manufacturer Contact
kate karberg
31 technology dr
irvine, CA 92618
3035526892
MDR Report Key16360482
MDR Text Key309370052
Report Number2029046-2023-00267
Device Sequence Number1
Product Code LPB
Combination Product (y/n)N
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Literature,Health Professional
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 02/12/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received02/13/2023
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Catalogue NumberUNK_SMART TOUCH BIDIRECTIONAL
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received01/30/2023
Was Device Evaluated by Manufacturer? No
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Treatment
CARDIOLAB (GENERAL ELECTRIC HEALTHCARE).; CARTO 3D.; LABSYSTEM PRO (BOSTON SCIENTIFIC).; PENTARAY NAV.; UNKNOWN NEEDLE ABLATION CATHETER.
Patient Outcome(s) Required Intervention; Life Threatening;
-
-